Inhibrx Biosciences, Inc. (INBX)
Nasdaq · Biological Products, (No Diagnostic Substances) · Manufacturing · CIK 2007919 · fiscal year ends in Dec
Closing price $73.44 on 29 Oct 2026; 52-week range $58.39 to $141.84.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $1.1B
- Cash
- $133.3M
- Debt
- $176.3M
- Shares outstanding
- 14.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $1.3M | -$135.0M | -$140.1M | -$9.04 | -$129.8M | 10-K filed 19 Mar 2026 |
| FY2024 | 31 Dec 2024 | $200.0K | -$331.4M | $1.7B | $112.62 | -$197.0M | 10-K filed 17 Mar 2025 |
| FY2023 | 31 Dec 2023 | $1.8M | -$219.2M | -$241.4M | -$20.48 | -$197.9M | 10-K filed 17 Mar 2025 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $0 | -$36.6M | -$2.34 |
| Q4 FY2025 | 31 Dec 2025 | $0 | -$32.8M | -$2.11 |
| Q3 FY2025 | 30 Sep 2025 | $0 | -$35.3M | -$2.28 |
| Q2 FY2025 | 30 Jun 2025 | $1.3M | -$28.7M | -$1.85 |
| Q1 FY2025 | 31 Mar 2025 | $0 | -$43.3M | -$2.80 |
| Q4 FY2024 | 31 Dec 2024 | $100.0K | -$47.9M | -$3.09 |
| Q3 FY2024 | 30 Sep 2024 | $0 | -$43.9M | -$2.84 |
| Q2 FY2024 | 30 Jun 2024 | $100.0K | $1.9B | $125.48 |
Company events
The newest 8-K filings of 27 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 28 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 8 Sep 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 16 Jul 2026 | 8-K | Material agreement, New debt, Share sale, Investor update | 1.01, 2.03, 3.02, 7.01, 9.01 |
| 15 Jun 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 3 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 11 May 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 21 Apr 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 19 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Feb 2026 | 8-K | Investor update | 7.01, 9.01 |
| 16 Dec 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 64 held.
| Filed | Form | Period |
|---|---|---|
| 28 Sep 2026 | 8-K | 28 Sep 2026 |
| 8 Sep 2026 | 8-K | 8 Sep 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 16 Jul 2026 | 8-K | 15 Jul 2026 |
| 15 Jun 2026 | 8-K | 15 Jun 2026 |
| 3 Jun 2026 | 8-K | 3 Jun 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 11 May 2026 | 8-K | 11 May 2026 |
| 23 Apr 2026 | ARS | 31 Dec 2025 |
| 23 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 14 Oct 2026 | Lappe Mark, Chief Executive Officer | Purchase | 2,470 | $84.07 | $207.7K | 743,018 | 14 Oct 2026 |
| 14 Oct 2026 | Lappe Mark, Chief Executive Officer | Purchase | 2,470 | $85.00 | $209.9K | 745,488 | 14 Oct 2026 |
| 14 Oct 2026 | Lappe Mark, Chief Executive Officer | Purchase | 100 | $85.76 | $8.6K | 170,000 | 14 Oct 2026 |
| 14 Oct 2026 | Lappe Mark, Chief Executive Officer | Purchase | 2,449 | $84.07 | $205.9K | 167,449 | 14 Oct 2026 |
| 14 Oct 2026 | Lappe Mark, Chief Executive Officer | Purchase | 2,451 | $85.00 | $208.3K | 169,900 | 14 Oct 2026 |
| 28 Sep 2026 | Lappe Mark, Chief Executive Officer | Purchase | 1,500 | $98.88 | $148.3K | 737,548 | 28 Sep 2026 |
| 28 Sep 2026 | Lappe Mark, Chief Executive Officer | Purchase | 3,000 | $101.70 | $305.1K | 740,548 | 28 Sep 2026 |
| 25 Sep 2026 | Lappe Mark, Chief Executive Officer | Purchase | 3,324 | $98.87 | $328.6K | 733,872 | 28 Sep 2026 |
| 25 Sep 2026 | Lappe Mark, Chief Executive Officer | Purchase | 2,176 | $99.60 | $216.7K | 736,048 | 28 Sep 2026 |
| 23 Sep 2026 | Kayyem Jon Faiz, Director | Purchase | 5,000 | $100.00 | $500.0K | 434,360 | 23 Sep 2026 |
| 16 Sep 2026 | Kayyem Jon Faiz, Director | Purchase | 5,000 | $100.00 | $500.0K | 429,360 | 17 Sep 2026 |
| 15 Sep 2026 | Manhard Kimberly, Director | Sale outside a trading plan | 500 | $105.05 | $52.5K | 7,500 | 15 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 15 Sep 2026 | MANHARD KIMBERLY, Director | 500 | $52.5K | 15 Sep 2026 |
| 14 Sep 2026 | MANHARD KIMBERLY, Director | 500 | $55.1K | 14 Sep 2026 |
| 11 Sep 2026 | MANHARD KIMBERLY, Director | 500 | $55.9K | 11 Sep 2026 |
| 9 Sep 2026 | MANHARD KIMBERLY, Director | 500 | $57.9K | 9 Sep 2026 |
| 8 Sep 2026 | MANHARD KIMBERLY, Director | 500 | $57.6K | 8 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 28 Oct 2026 | BANK OF AMERICA CORP /DE/ | 13G amended | 2.4% | 357.3K |
| 14 Aug 2026 | Schonfeld Strategic Advisors LLC | 13G | 5.33% | 781.7K |
| 14 Aug 2026 | Perceptive Advisors LLC | 13G amended | 9.99% | 1.5M |
| 14 Aug 2026 | VIKING GLOBAL INVESTORS LP | 13G amended | 9.3% | 1.4M |
| 3 Aug 2026 | BANK OF AMERICA CORP /DE/ | 13G | 5.9% | 857.3K |
| 15 May 2026 | Perceptive Advisors LLC | 13G amended | 9.99% | 1.5M |
| 15 May 2026 | VIKING GLOBAL INVESTORS LP | 13G amended | 9.99% | 1.5M |
| 17 Feb 2026 | VIKING GLOBAL INVESTORS LP | 13G amended | 9.99% | 1.5M |
| 11 Feb 2026 | Morgan Stanley | 13G | 7.9% | 1.2M |
| 21 Jan 2026 | BlackRock, Inc. | 13G | 5.3% | 768.1K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 3.4M | -0.45% | 16.83 |
| 30 Sep 2026 | 3.4M | +1.15% | 11.82 |
| 15 Sep 2026 | 3.4M | +2.9% | 8.31 |
| 31 Aug 2026 | 3.3M | +2.57% | 10.39 |
| 14 Aug 2026 | 3.2M | -3.77% | 14.39 |
| 31 Jul 2026 | 3.3M | -2.7% | 15.64 |
| 15 Jul 2026 | 3.4M | -0.38% | 9.04 |
| 30 Jun 2026 | 3.4M | +4.47% | 9.91 |
Funds that hold it
From each fund's latest Form 13F.
183 funds held it at 30 Jun 2026: 101 added and 39 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Morgan Stanley | 1,308,051 | $123.9M | +44,973 |
| Perceptive Advisors LLC | 1,297,763 | $123.0M | -144,944 |
| Sanofi | 1,157,926 | $109.7M | 0 |
| Viking Global Investors LP | 1,123,929 | $106.5M | -313,776 |
| HighTower Advisors, LLC | 870,551 | $82.5M | +351 |
| Bank of America Corp. | 841,141 | $79.7M | +808,458 |
| BlackRock, Inc. | 825,972 | $78.3M | +27,074 |
| Schonfeld Strategic Advisors LLC | 697,586 | $66.1M | +442,759 |
| State Street Corp. | 640,458 | $60.7M | +89,613 |
| Vanguard Capital Management LLC | 492,477 | $46.7M | +6,055 |
Peers
Companies in the same industry.
- Amgen Inc. (AMGN): revenue $38.1B, market value $249.1B
- Gilead Sciences, Inc. (GILD): revenue $30.5B, market value $205.5B
- Moderna, Inc. (MRNA): revenue $2.2B, market value $88.9B
- argenx SE (ARGX): revenue $4.2B, market value $55.5B
- Biogen Inc. (BIIB): revenue $10.3B, market value $36.9B
- BioNTech SE (BNTX): revenue $3.2B, market value $22.4B
- Exelixis, Inc. (EXEL): revenue $2.5B, market value $16.2B
- Halozyme Therapeutics, Inc. (HALO): revenue $1.7B, market value $15.0B
- Neurocrine Biosciences Inc. (NBIX): revenue $3.4B, market value $14.9B
- Bio-Techne Corp. (TECH): revenue $1.2B, market value $11.3B